Logo

Azurity’s Fleqsuvy Receives the US FDA’s Approval for the Treatment of Spasticity Associated with Multiple Sclerosis

Share this

Azurity’s Fleqsuvy Receives the US FDA’s Approval for the Treatment of Spasticity Associated with Multiple Sclerosis

Shots:

  • The US FDA has approved Azurity’s Fleqsuvy (baclofen oral suspension) as a concentrated formulation for the treatment of spasticity related to MS or patients with spinal cord injuries and other spinal cord diseases
  • The approval was based on a bioavailability study to evaluate baclofen (oral tablet) vs Fleqsuvy in healthy adults with the same indication. The results showed similar bioavailability of baclofen at 20mg dose level for the oral suspension and oral tablet formulations in the fasting conditions
  • Fleqsuvy is supplied as a 25mg/5mL (5mg/mL) oral grape-flavored suspension and is available in bottles of 120mL or 300mL

Ref: PR Newswire | Image: Azurity

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions